TITLE

US pharma company fined $435 million

PUB. DATE
October 2006
SOURCE
CMAJ: Canadian Medical Association Journal;10/24/2006, Vol. 175 Issue 9, p1046
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that Schering-Plough Corp. has agreed to pay fines to settle criminal and civil charges that it illegally promoted several drugs. The company has reached the agreement with the U.S. Justice Department. According to U.S. deputy attorney general Paul McNulty, the settlement sends a clear message to the pharmaceutical industry that the Justice Department will not tolerate deceptive and illegal marketing practices.
ACCESSION #
22736997

 

Related Articles

  • Firms need to understand key memos addressing corruption. McCarty, Mark // Medical Device Daily;6/21/2007, Vol. 11 Issue 119, p1 

    The article reports that Camille Conway, a partner at Barnes & Thornburg, presented a lecture before the attendees of the Medical Device and Diagnostics Marketing Compliance Congress concerning a memo issued by U.S. deputy attorney general Paul McNulty in December 2006. The McNulty memo modifies...

  • Another Black Eye for Big Pharma.  // njbiz;4/7/2008, Vol. 21 Issue 15, p10 

    The article talks about the rage over cholesterol-fighting drugs Vytorin and Zetia. It states that this incident impacted on Schering-Plough and Merck, the developers of Vytorin, which has damaged Schering-Plough in particular. The widespread criticism focused on the question regarding the...

  • Drug firms boost pitch directly to consumers. Miller, Cyndee // Marketing News;11/21/94, Vol. 28 Issue 24, p1 

    The article focuses on the marketing strategy employed by pharmaceutical industry in the United States. A relationship marketing program for patients was developed by Merck & Co. Inc. by using its prostate drug. Other companies provide advertising for its prescription drugs and introduces new...

  • Schering-Plough is accused of overcharging and of obstructing justice. Charatan, Fred // BMJ: British Medical Journal (International Edition);6/7/2003, Vol. 326 Issue 7401, p1233 

    Discusses how Schering-Plough, of Kenilwoth, New Jersey, is facing indictment on a number of charges listed in a letter from the U.S. Attorney's office. Charges which include giving financial grants and other items of value to doctors and other customers, marketing drugs for unapproved uses and...

  • 'Switch hits' juice '07 OTC lineup.  // Drug Store News;1/15/2007, Vol. 29 Issue 1, p49 

    The article reports on the number of over-the-counter medicine with switch or dual status that are expected to be marketed in the first quarter of 2007 in the U.S. One of them is Alli, a weight-loss drug from GlaxoSmithKline which received an approvable letter from the Food and Drug...

  • Healthcare Campaign of the Year 2010.  // PRWeek (U.S. Edition);2010 Awards Supplement, p14 

    The article reports on Pfizer Inc.'s Medicines Assistance for Those Who Are In Need (MAINTAIN) program which won the Healthcare Campaign of the Year at the 2010 PR Week Awards in the U.S. It mentions that the program gives unemployed people free prescription drugs. It also cites the online...

  • Success from two sources. Iskowitz, Marc // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p44 

    The article focuses on the overwhelming success of the cholesterol drug Vytorin, a drug used to treat high cholesterol from Merck and Co. and Schering-Plough Corp. It was stated that Vytorin has been considered to be the fastest growing product in the highly competitive cholesterol treatment...

  • Pharma Makers Post Lackluster Third Quarter Results. Jarvis, Lisa // Chemical Market Reporter;10/29/2001, Vol. 260 Issue 16, p10 

    Discusses the earnings posted by major pharmaceutical firms in the United States for the third quarter of fiscal 2001. Percentage increase in the sales of some drugs from Bristol-Myers Squibb Co.; Factors which contributed to the slow down in drugs sales at Schering-Plough company; Forecast on...

  • Thompson Memorandum Revised: U.S. Deputy Attorney General Paul J. McNulty Changes Guidelines for Prosecuting Corporate Fraud.  // Venulex Legal Summaries;2006 Q4, p1 

    The article discusses the revisions made by the U.S. Department of Justice (DOJ) to its guidelines for deciding when to seek an indictment of a corporation. Specifically, the guidelines issued by U.S. Deputy Attorney General Paul J. McNulty addresses the circumstances under which prosecutors may...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics